Heart Attack |
Acute Myocardial Infraction; Myocardial Infarction |
Clinical Trial: Natural History of Stroke: Cause and Development
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to learn more about stroke and obtain information that may serve as the basis for future investigations. It will 1) establish a registry of patients with cerebrovascular disease (stroke); 2) characterize the natural history of acute stroke and transient ischemic attacks (TIA)-an interruption of blood flow to the brain that causes stroke symptoms for a short period of time); and 3) evaluate the data to generate ideas for future studies.
Patients 18 years of age or older with suspected acute stroke or TIA may be eligible for this study. Subjects will be recruited from patients who present with stroke at the emergency department of Suburban Hospital in Bethesda, Maryland.
The study will gather data collected from diagnostic and laboratory tests the patient undergoes as part of standard medical care, including findings of medical and neurological examinations and other tests. In addition, studies will be done for research purposes only to gather data about stroke and TIA. These may include the following:
- Electrocardiogram (EKG) (heart tracing)-electrodes placed on the chest wall detect the heartbeat and heart rhythm.
- Computed tomography (CT) scan of the head-specialized X-rays are used to obtain images of the brain.
- Magnetic resonance imaging (MRI) of the brain-a strong magnetic field and radio waves are used to produce images that provide information about the brain tissue and blood vessels.
- Transcranial Doppler (TCD)-sound waves are used to image the arteries of the brain and neck.
- Echocardiogram-sound waves are used to image the heart and evaluate heart function.
Patients may be asked to return to Suburban Hospital for follow-up testing in 1, 3, and/or 12 months, when some of these tests may be repeated to assess changes over time
| Condition |
|---|
| Cerebrovascular Accident Transient Ischemic Attack |
MedlinePlus related topics: Stroke; Transient Ischemic Attack
Study Type: Observational
Study Design: Natural History
Official Title: Evaluation, Pathogenesis, and Treatment of Patients with Cerebrovascular Disease
Expected Total Enrollment: 2000
Study start: January 19, 2001
OBJECTIVE: This is a natural history/disease pathogenesis protocol for evaluation of patients with suspected acute stroke, transient ischemic attack (TIA), or other disturbances of cerebrovascular circulation. The purpose of this protocol is to generate natural history data to serve as the basis for future hypothesis-driven protocols as well as to contribute to the clinical and physiological understanding of cerebrovascular disease through the description of disease manifestations and the relationship among clinical, hematologic, and radiologic variables.
STUDY POPULATIONS: Patients will be recruited from the collaborative stroke program between NINDS and affiliated hospitals and will be followed for the duration of their hospitalization. Select patients will then be seen for follow-up for up to 5 years.
DESIGN: Clinical issues to be addressed will include disease manifestations, natural history, acute disease management, and psychological/behavioral impact of the disease. Because of the nature of acute cerebrovascular disease, it is important to note that the research performed under this protocol will not interfere with emergency clinical evaluation or treatment of patients, as specified in the clinical care pathway in place for the standard care of stroke patients at participating hospitals. Due to the emergency nature of clinical evaluation and therapy for stroke patients, waiver of written informed consent in certain circumstances for minimal risk procedures (e.g., collecting extra tubes of blood during initial phlebotomy for emergency room blood tests) will be required when it is impossible to obtain consent prior to critical emergency treatment procedures that may change the values of the variables. Patients will not be treated with experimental therapies as part of this protocol.
OUTCOME MEASURES: In addition to clinical, imaging and laboratory data that are part of routine clinical care of the patient, a variety of outcomes will be collected, e.g., infarct volume, clinical outcomes on NIH Stroke Scale, modified Rankin Score, Barthel Index, blood marker of inflammation and coagulation. Statistical analysis plans will be developed as specific questions and hypotheses are generated.
Eligibility
Genders Eligible for Study: Both
Criteria
Patients will be recruited for enrollment in this protocol during the acute (less than 48 hours) phase of disease from the Stroke Program at the participating hospital.
EXCLUSION CRITERIA:
Patients is less than 18 years of age.
Patients with contraindication to MRI scanning will be excluded from any testing which involves the use of MRI. These contraindications include patients with the following devices or conditions:
a) Central nervous system aneurysm clips;
b) Implanted neural stimulator;
c) Implanted cardiac pacemaker or defibrillator;
d) Cochlear implant;
e) Ocular foreign body (e.g. metal shavings);
f) Insulin pump;
g) Metal shrapnel or bullet;
h) Any implanted device that is incompatible with MRI.
Patients with a condition precluding entry into the scanner (e.g. morbid obesity, claustrophobia, etc.) will not be included in the MRI portion of this study.
Pregnant or lactating women will be excluded from studies involving the administration of contrast agents.
Pregnant women will be excluded from CT scans specific to this protocol.
Location and Contact Information
Maryland
National Institute of Neurological Disorders and Stroke (NINDS), 9000 Rockville Pike, Bethesda, Maryland, 20892, United States; Recruiting
TTY 1-866-411-1010
More Information
Detailed Web Page
Publications
Williams GR, Jiang JG, Matchar DB, Samsa GP. Incidence and occurrence of total (first-ever and recurrent) stroke. Stroke. 1999 Dec;30(12):2523-8.
Brown RD Jr, Petty GW, O'Fallon WM, Wiebers DO, Whisnant JP. Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. Stroke. 1998 Oct;29(10):2109-13.
Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina PL, Yatsu FM, Grotta JC. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke. 1998 Jan;29(1):18-22.
Record last reviewed: February 1, 2005
Last Updated: February 24, 2005
Record first received: January 24, 2001
ClinicalTrials.gov Identifier: NCT00009243
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- 9-1-1: Rapid Identification and Treatment of Acute MyocardialInfarction (National Heart, Lung, and Blood Institute Information Center, NHLBI, NIH, HHS)
- ACE Inhibitors after Heart Attacks: Varying Effects? (American College of Physicians)

Not Signed In -

